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Abstract
Background: As a first step to identify novel potential biomarkers for prenatal Down Syndrome screening, we analyzed
gene expression in embryos of wild type mice and the Down Syndrome model Ts1Cje. Since current Down Syndrome
screening markers are derived from placenta and fetal liver, these tissues were chosen as target.
Methodology/Principal Findings: Placenta and fetal liver at 15.5 days gestation were analyzed by microarray profiling. We
confirmed increased expression of genes located at the trisomic chromosomal region. Overall, between the two genotypes
more differentially expressed genes were found in fetal liver than in placenta. Furthermore, the fetal liver data are in line
with the hematological aberrations found in humans with Down Syndrome as well as Ts1Cje mice. Together, we found 25
targets that are predicted (by Gene Ontology, UniProt, or the Human Plasma Proteome project) to be detectable in human
serum.
Conclusions/Significance: Fetal liver might harbor more promising targets for Down Syndrome screening studies. We
expect these new targets will help focus further experimental studies on identifying and validating human maternal serum
biomarkers for Down Syndrome screening.
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Introduction
Prenatal screening for Down Syndrome (DS) has been routinely
available for two decades. Typically, such screening procedures
consist of a risk calculation based on maternal age, nucal
translucency and serum biomarker measurements, after which
women with a high predicted risk can opt for invasive testing such
as amniocentesis or chorionic villus sampling. Initially, the most
commonly used method for risk calculation was the second
trimester triple test, which combines serum levels for alpha-
fetoprotein (AFP), unconjugated estriol (uE3), and the free b
subunit of human chorion gonadotrophin (fb-hCG) with maternal
age [1,2]. Currently, many countries including the Netherlands,
have replaced this by the first trimester combined test, which is
based on fb-hCG and pregnancy-associated plasma protein A
(PAPP-A) serum concentrations, ultrasound nuchal translucency
(NT) measurements and maternal age [3]. This latter test has a
Detection Rate (DR) of 75–85% at a 5% false positive rate (FPR)
[4–6]. Although the reliability of the first trimester combined test is
better than the triple test, both the DR and the FPR are still in
need for improvement, and a lot of international effort has been
put in improving both kinds of prenatal tests.
A promising approach to improve DS screening is by adding
multiple biochemical markers to the serum analysis. By means of
innovative proteomics, genomics, and bioinformatics approaches,
novel discriminative markers can be identified that, when added to
the current serum assays, can improve the DR and FPR [7–12].
Serum markers used in these two routinely used screening tests
essentially originate from two tissues, namely fetal liver (AFP) and the
placenta (fb-hCG, PAPP-A), whereas the non-protein serum
biomarker uE3 is produced by the placenta from its precursor
dehydroepiandrosterone sulfate produced by the fetal liver and
adrenal glands. We thereforehypothesizethat placenta and fetal liver
harbor additional biomarkers suitable for improving DS screening,
and have set up a research strategy to identify them. Availability of
fetal human material for DS cases or controls is limited and therefore
existing human studies are restricted to placenta or cultured
trophoblasts [13–16]. Additionally, when human material is
available, genomics and proteomics studies are inevitably complicat-
ed by sources of variation from maternal, fetal, and clinical origin.
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animal models. For ethical and practical reasons, mouse models
are preferable for such studies, and fortunately several mouse
models are available mimicking human Down syndrome [17–24].
In this study we used the Ts1Cje mouse strain [21], which contains
a segmental trisomy of mouse chromosome 16 (Mmu16) distal of
the Sod1 gene, including a region orthologous to the region of
human chromosome 21 commonly associated with Down
Syndrome: the ‘‘Down Syndrome critical region’’ [21]. We
selected a mouse model in which the Mmu16 trisomic region
extends beyond the DSCR, as comparative genetic studies [25,26]
have indicated that trisomy for only the DSCR is not sufficient for
a complete DS phenotype. Ts1Cje mice have been shown to
display a recognizable DS phenotype which consists of craniofacial
malformations including a smaller cerebellum volume, as well as
learning and behavioral abnormalities [17,21,27].
In this study, fetuses were obtained from wild type mothers bred
with either wild type or Ts1Cje males. Gene expression profiles in
fetal liver and placenta of wild type and Ts1Cje fetuses were
compared and for differentially expressed genes it was examined if
they code for blood detectable proteins and/or are involved in
clinically involved processes. With this strategy, we have identified
a number of targets with potential for further studies ultimately
aimed at biomarker application in human prenatal DS screening.
Materials and Methods
Ethics statement
This study was agreed upon by the Animal Experimentation
Ethical Committee of our institute under permit number
200900176. Animal handling in this study was carried out in
accordance with relevant Dutch national legislation, including the
1997 Dutch Act on Animal Experimentation.
Animal studies
The trisomic B6EiC3Sn-Ts(16C-tel)1Cje1 mice, also named
Ts1Cje, contain an additional copy of distal chromosome 16 [21].
Trisomic B6EiC3Sn-Ts(16C-tel)1Cje1 mice (genotype Ts/+) and
wild type hybrid background B6EiC3SnF1/J mice (genotype +/+)
were purchased from the Jackson laboratory (Bar Harbor, ME,
USA).
To obtain Ts1Cje and wild type fetuses for RNA isolation, male
+/+ mice (control group) or male Ts/+ mice (Down group) were
bred with female breeding mice of the C3H/HeNHsd strain
(Harlan, Horst, the Netherlands) at 8–10 weeks of age. After
mating, females were separated and pregnant females were
identified through scoring of vaginal plugs (embryonic time point
E0.5 in days). Females were sacrificed on E15.5 using CO2/O2.
From pregnant mice all embryos were collected and every single
embryo was processed further. Placenta and fetal liver were
collected for RNA extraction and paws were collected for DNA
extraction and genotyping. All tissues were immediately frozen in
liquid nitrogen and stored at 280uC until further processing.
DNA extraction, embryo genotyping and sex
determination
Genomic DNA was extracted from embryo paws. Genotyping
and sex determination on mice embryos were both performed by
multiplex PCR using primer sequences given in Supporting
Dataset S1. Each PCR contained 5 ml2 6 Hotstar Master Mix
(Qiagen), 0.5 mM of each primer and 10–50 ng genomic DNA, in
a total volume of 10 ml. PCR reactions were carried out in a
Perkin-Elmer 9600 thermal cycler under the following conditions:
95uC for 15 min; 30 cycles of 94uC for 30 sec, 55uC for 30 sec,
72uC for 1 min; followed by 72uC for 10 min.
RNA isolation, yield and quality
RNA was extracted from placenta and fetal liver using the
miRNeasy kit (Qiagen). RNA concentrations were measured using
a NanoDrop spectrophotometer (NanoDrop Technologies, Wil-
mington, DE, USA). The integrity of the RNA samples was
determined with the BioAnalyzer (Agilent Technolgies, Amstelv-
een, The Netherlands) using the RNA nano 6000 kit (Agilent
Technologies) yielding RIN-values $9.6. For placenta and fetal
liver, microarray analysis was carried out using RNA samples of
24 individual embryos, i.e. six male and six female embryos from
both genotypes.
Amplification and labeling protocol
Per sample, 500 ng total RNA was amplified according to the
Agilent QuickAmp kit manual (Agilent technologies). Amino-allyl
modified nucleotides were incorporated during the aRNA
synthesis (2.5 mM rGAU (GE Healthcare), 0.75 mM rCTP (GE
Healthcare), 0.75 mM AA-rCTP (TriLink Biotechnologies). Syn-
thesized aRNA was purified with the E.Z.N.A. MicroElute RNA
Clean Up Kit (Omega Bio-Tek). Test samples were labeled with
Cy3 and a Reference sample (made by pooling equimolar amounts
of RNA from Test samples) was labeled with Cy5. Next, 5 mgo f
aRNA was dried down and dissolved in 50 mM carbonate buffer
pH 8.5. Individual vials of Cy3/Cy5 from the mono-reactive dye
packs (GE Healthcare) were dissolved in 200 ml DMSO. To each
sample, 10 ml of the appropriate CyDye dissolved in DMSO was
added and the mixture was incubated for 1 h. Reactions were
quenched with the addition of 5 ml 4 M hydroxylamine (Sigma-
Aldrich). The labeled aRNA was purified with the E.Z.N.A.
MicroElute RNA Clean Up Kit. The yields of aRNA and CyDye
incorporation were measured on the NanoDrop ND-1000.
Microarray hybridization, scanning & data processing
Each hybridization mixture consisted of 1.1 mg Test (Cy3) and
1.1 mg Reference (Cy5) sample. Samples were dried and 1.98 mlo f
the appropriate sample tracking control (STC, Roche Nimblegen)
was added. The hybridization cocktail was made according to the
manufacturer’s instructions (Nimblegen Arrays User’s Guide –
Gene Expression Arrays Version 5.0, Roche Nimblegen). From
this mix, 5.22 ml was added to each sample. The samples were
incubated for 5 min at 95uC and 5 min at 42uC prior to loading.
Hybridization samples were loaded onto a 126135 k Mus musculus
microarray (Catalog no. 05543797001, Design 090901 MM9
EXP HX12) containing probes for 44,170 genes with 3 spots per
target probe. Microarrays were hybridized for 20 hours at 42uC
with the NimbleGen Hybridization System 4 (Roche Nimblegen).
Afterwards, the slides were washed according to the Nimblegen
Arrays User’s Guide – Gene Expression Arrays Version 5.0 and
scanned in an ozone-free room with a Agilent DNA microarray
scanner G2565CA (Agilent Technologies). Feature extraction was
performed with NimbleScan v2.5 (Roche Nimblegen). Each
microarray corresponded to labeled RNA from one individual
embryo.
Data analysis
Complete raw and normalized microarray data and their
MIAME compliant metadata have been deposited at GEO (www.
ncbi.nlm.nih.gov/geo) under accession number GSE24272.
Raw microarray signal data were normalized in R (www.r-
project.org), using a four step approach [28]: (1) natural log-
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correcting the sample spot signal for the corresponding reference
spot signal and (4) averaging data from replicate probe spots.
Normalized data for the resulting 44170 probes were further
analyzed in R and Microsoft Excel.
For both placenta and liver, gene expression differences
between either sex or genotype were compared with an ANOVA.
Obtained p-values were corrected for multiple testing by
calculating the false discovery rate (FDR) according to Benjamini
and Hochberg [29]. Probes with a False Discovery Rate
(FDR),0.05 were considered significant. When multiple probes
corresponding to the same gene were significant, their data were
averaged to remove redundancy in further analysis. Probes with
significant expression differences between male and female
embryos were excluded from the analysis on genotype differences.
Hierarchical clustering analysis was performed using Gene-
Maths XT (Applied Maths, St-Martens-Latem, Belgium) using
Euclidean distance and Ward linkage. Functional Annotation and
Gene Ontology (GO) term enrichment were examined with the
DAVID Bioinformatics Resource (http://david.abcc.ncifcrf.gov)
[30]. Enrichment for tissue-specific or literature-based functional
gene sets was determined in R using an in-house developed
algorithm based on the DAVID methodology. Tissue- or lineage-
specific gene sets were obtained from data downloaded from the
BioGPS website (http://biogps.gnf.org) [31,32] as well as other
relevant literature sets [33–35].
Groupwise regulation of Gene Ontology categories and above-
mentioned custom gene sets were determined by Gene Set
Enrichment Analysis (GSEA) [35] using default analysis param-
eters. Gene sets were considered regulated if the GSEA p-value
was,0.05 and the FDR was ,0.10.
To determine which genes code for proteins detectable in
human serum, we determined which proteins are annotated in
Gene Ontology as extracellular, in UniProt as secreted, or have
been experimentally detected in the Human Plasma Proteome
project [36].
Quantitative RT-PCR
Microarray results were for a subset of genes verified by
quantitative RT-PCR analysis on RNA from 12 Ts1Cje versus 12
WT samples. For this, all reagents, methods and equipment were
obtained from Applied Biosystems. TaqMan gene expression
assays used are given in Supplementary Dataset S2. Assays for Hprt
and Polr2a were custom-made and included as endogenous
controls. After RNA samples were reverse transcribed to cDNA,
qPCR was performed on 125 ng of cDNA using the 7500 Fast
real-time PCR system. Threshold cycles were automatically
derived from the amplification plots constructed of the ROX-
normalized fluorescence signals by 7500 Fast system SDS software
v1.3. The average of the Hprt and Polr2a level per cDNA sample
was used to normalize the expression of the other genes. Relative
quantification of the mRNA copies in the Ts1Cje samples
compared to that of the WT samples was performed by the
comparative threshold cycle method using Microsoft Excel.
Results
Genotype confirmation
To validate the use of a mouse model for DS in a
transcriptomics study, we first compared the expression ratio
between Ts1Cje and WT embryos for genes located on
chromosome Mmu16. Plotting the gene expression ratio against
the chromosomal position (Fig. 1) reveals an increased expression
for genes in the segmental trisomic locus in both fetal liver and
placenta.
Sex-specific gene regulation
Comparing differences in expression levels between male and
female embryos of either genotype revealed 31 significant probes
(12 genes) in fetal liver and 25 significant probes (11 genes) in
placenta. When combined, this resulted in 16 genes for which
corresponding probes were excluded from the analysis of genotype
differences. Briefly, 7 genes were male-specific genes and 9 female-
Figure 1. Chromosome plot of Mmu16 with gene expression ratios between Ts1Cje and wild type mice. Significant genes (FDR 5%) are
indicated in blue. The border of the trisomic locus is indicated with a vertical red line.
doi:10.1371/journal.pone.0018866.g001
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either of the sex chromosomes.
Genotype-specific gene expression in fetal liver
For fetal liver, we found significant genotype-related expression
changes for 152 probes, corresponding to 109 genes (Supporting
Dataset S3). As indicated in the heatmap in Fig. 2, the majority of
these (95 genes) are induced in fetal livers of Ts1Cje mice of either
sex, with the other 14 being suppressed. Of these, 51 are mapped
on the corresponding trisomic locus (Fig. 1).
Functional overrepresentation analysis shows that among the
genes with differential expression, there is enrichment for genes
involved in immunology and hematopoiesis, including such genes
as the calgranulin A and B subunits (S100a8, S100a9), lacto-
Figure 2. Heatmap for fetal liver and placenta.
doi:10.1371/journal.pone.0018866.g002
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platelet factor 4 (Pf4), pleckstrin (Plek), pro-platelet basic protein
(Ppbp), and the gene for the zeta hemoglobin chain (Hbb-bh1). This
enrichment is especially strong among genes that are induced in
Ts1Cje mice but are not located on the trisomic locus. Among
these non-locus genes, significantly enriched gene sets are mainly
associated with the myeloid and neutrophil lineages. Among genes
with lower expression in Ts1Cje fetal liver, there is significant
overrepresentation of genes associated with or expressed in the
platelet lineage.
Threshold-free pathway analysis using GSEA indicated that
Ts1Cje mice have increased pathway activity in several GO-terms
related to hematopoiesis (e.g. leukocyte differentiation, response to
virus, response to biotic stimulus) and metabolism (alcohol
metabolic process, glycerolipid metabolism, glycolysis and gluco-
neogenesis). Several custom gene sets related to interferon
response, myeloid lineage, and (neutrophilic) granulocytes were
induced in Ts1Cje whereas the opposite effect was found for terms
related to platelets and (B- and T-) lymphocytes. Excluding the
trisomic locus from the data used in the analysis did not
significantly change these findings.
Among the 95 genes with significant expression differences in
liver, there are 24 that encode for proteins potentially detectable in
human blood (Supporting Dataset S3, Table 1). Of these, only 7
are located at the trisomic locus. Many of the other blood-
detectable proteins are associated with either neutrophils or
platelets.
Genotype-specific gene expression in placenta
Gene expression profiling for placental RNA revealed 75 probes
with statistical significance, corresponding to 48 genes (Fig. 2,
Supporting Dataset S3). For this tissue, induced expression in the
Ts1Cje placentas was found for 47 genes, 41 of which are located
on the trisomic locus (Fig. 1). Only one gene (Sp4) was suppressed
in Ts1Cje mice. No significant overrepresentation for pathways or
other gene sets was found among placenta-regulated genes.
GSEA found no significant pathway-level effect among GO-
terms, and among the custom gene sets included, significant scores
were only observed for leukocytes, especially neutrophils. Howev-
er, significance was less pronounced than in fetal liver and
excluding the trisomic locus further reduced the extent of this
effect.
Among the genes regulated in placenta, 8 have human
homologs that are blood- detectable at the protein level
(Supporting Dataset S3, Table 1). With the exception of Fgfbp3,
these are the same 7 markers located on the trisomic locus as for
the fetal liver.
Overlap
The overlap between regulated genes in placenta and fetal liver
comprises 42 genes. Of these, 40 are located in the trisomic region,
of which 7 genes encode for potentially blood-detectable proteins
(C2cd2, Dyrk1a, Ifnar2, Morc3, Sfrs15, Sod1, Tmprss2). Of the two
genes that are not located on the trisomic locus, Ifi27l1 was
increased and Sp4 had decreased expression in Ts1Cje mice
compared to WT mice. For neither of these two genes there is
evidence for protein detectability in human blood.
Quantitative RT-PCR verification
For two genes with increased expression in Ts1Cje placenta as
well as fetal liver (Sod1 and Dyrk1a) and four with differential
expression in Ts1Cje fetal liver (Pf4, Ppbp, S100a8, S100a9)w e
performed quantitative RT-PCR (Supporting Dataset S2). For all
of these six genes, we confirmed their differential expression as well
as their significance at p,0.05. The direction of change was in
agreement for all assays. Expression changes measured by PCR
were comparable to those measured by microarray, with the
median difference between microarray versus RT-PCR ratios
being 11% (Supporting Dataset S2).
Discussion
Gene expression profiling in animal models has been previously
successfully applied to gain insight and discover novel protein
biomarkers for detection of human diseases [37–39]. For DS,
several mouse models have been developed to study the effect of
trisomy in single or multiple genes on DS phenotype and
development (reviewed in [17,18]). Of these models, the Ts1Cje
and Ts65Dn mice have so far been used most for gene expression
analysis on brain tissue [40–44] and to a lesser extent on other
adult tissues [45,46]. In this study, we describe for the first time
gene expression analysis on fetal tissue of DS model mice with the
ultimate goal to identify potential biomarkers applicable for
prenatal serum screening. Although over a dozen mouse models
for DS have been described in the literature, not all of these are
Table 1. Potential blood-detectable biomarkers regulated in
fetal liver or placenta.
Gene symbol
Ratio fetal
liver
Ratio
placenta Chromosome
Induced in Ts1Cje mice (at DS locus)
C2cd2 1.173 1.370 16
Dyrk1a 1.290 1.282 16
Ifnar2 1.525 1.375 16
Morc3 1.372 1.340 16
Sfrs15 1.166 1.185 16
Sod1 1.796 1.881 16
Tmprss2 1.629 1.514 16
Induced in Ts1Cje mice (outside DS locus)
Camp 1.724 NS 9
Dpp4 1.178 NS 2
Isg15 1.947 NS 4
Lcn2 1.486 NS 2
Lifr 1.238 NS 15
Ltf 1.981 NS 9
Mmp8 1.532 NS 9
Mmp9 1.469 NS 2
Olfm4 1.895 NS 14
Pglyrp1 1.124 NS 7
Pnliprp2 1.345 NS 19
S100a8 1.769 NS 3
S100a9 1.922 NS 3
Fgfbp3 NS 1.178 19
Suppressed in Ts1Cje mice
Ccl24 21.221 NS 5
Pf4 21.259 NS 5
Plek 21.346 NS 11
Ppbp 21.336 NS 5
NS: not significant.
doi:10.1371/journal.pone.0018866.t001
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expression comparisons during fetal development. In mouse
models with trisomies for only single genes, the phenotype is less
pronounced whereas, on the other hand, mouse models with
trisomies for larger segments or even an entire chromosome tend
to suffer from male infertility or fetal death. The Ts1Cje mouse
shows a recognizable DS phenotype while still allowing for
breeding, and was consequently chosen as a model in this study.
Gene expression data were compared in fetal liver and placenta
between Ts1Cje and wild type embryos of both sexes at gestational
age 15.5 days. This age corresponds to the developmental phase at
the end of the first trimester in humans (Carnegie stage 22).
Because the combined first trimester test is carried out at this time
point, the corresponding mouse gestational age was chosen as the
optimal time point for DS biomarker discovery.
As expected, gene expression data showed an increased
expression of genes located in the trisomic locus (Fig. 1). This is
in agreement with the gene dosage effect described earlier in
human DS as well as mouse models [41–43,45–47]. In addition, in
each tissue we observed sex-specific expression differences for
some genes, most of which were located on either the X or Y
chromosome. However, for eventual human implementation in a
pregnancy screening program, markers should not show sex-
specific differences. Firstly, because the accuracy of the screening
program (DR and FPR) will benefit most from DS-markers that
are applicable to both male and female embryos. Additionally, if
sex-specific markers were to be included in a blood test, this would
complicate the counseling to pregnant women. Therefore, in this
study, these sex-specific markers were primarily identified in order
to be excluded from the main analysis.
Comparing fetal liver RNA from Ts1Cje with wild type
embryos, we found differential expression for 109 genes, of which
slightly more than half (58 genes) were outside the trisomic locus.
Remarkably, functional enrichment is stronger among these 58
genes than among the 109 genes as a whole. This indicates that
although a large fraction of the differentially expressed genes are
located in the same chromosomal regions, the main functional
effect is due to genes from multiple other chromosomes.
Functional enrichment analysis provided evidence that in Ts1Cje
fetal liver there was an increased expression in immune- en
hematopoiesis-related genes, more specifically of those expressed
in the (early) myeloid and neutrophil lineages, with a concurrent
lower expression of platelet-associated genes. As the fetal liver
represents the major organ of hematopoietic development during
the fetal period in mice as well as in humans, these findings
indicate a disturbed hematopoiesis in fetal Ts1Cje mice. Humans
with DS also suffer from various hematological abnormalities,
including thrombocytopenia, neutrophilia, and macrocytosis. For
example, around 10% of human DS newborns have transient
megakaryoblastic leukemia. This disease is unique to DS and
constitutes proliferation of immature megakaryoblasts. In most
cases, this disorder resolves later in life, but in 20–30% it develops
into acute megakaryocytic leukemia [48]. Carmichael et al.
described that although Ts1Cje mice do not develop either of
the two leukemic disorders, fetal liver hematopoiesis is nevertheless
perturbed in Ts1Cje mice [49], with the main defects in the
hematopoietic stem cell and myeloid progenitor cell compartments
[49]. Their findings are reflected in the gene expression data
described in this study and the functional parallels between murine
and human fetal hematopoiesis abnormalities indicates that these
markers can be prioritized with regard to human follow-up studies.
Placental gene expression data show differential expression for
48 genes. Most of these genes can be ascribed to gene dosage
effects of the trisomic locus at Mmu16. Functionally, there is no
significant overrepresentation of functional categories among the
differentially expressed genes, although GSEA indicates increased
levels of neutrophil-associated genes. In light of the data found for
fetal liver, this probably does not indicate an effect occurring
primarily in the placenta, but rather results from an increased
neutrophil count throughout the embryos as a whole, being
detected in the placenta as this tissue is rich in blood vessels.
Increased levels in the placenta could lead to increased fetal-
maternal exchange of the associated proteins, which could be
detected in a screening assay provided they exceed the background
variation in maternal blood.
We detected only a small number of non-trisomic genes
differentially regulated in placenta. Furthermore, we could not
detect a significant effect in Pappa (Papp-a, ratio 21.01, p=0.627)
or in other placental genes that have been described as biomarkers
for DS (e.g. Adam12: ratio=21.01, p=0.397; Inha: ratio=21.00,
p=0.271; Pgf (Plgf): ratio=1.02, p=0.648). It should be noted
here that mice lack the genes corresponding to b-hCG or PP13
and therefore these particular comparisons cannot be made.
Although it should not be taken for granted that Ts1Cje mice are a
suitable model for serum biomarker discovery regarding human
DS screening, our finding does not stand on its own. Comparable
studies using human placental(-) samples also could not verify gene
expression changes for known screening biomarkers [13–16]. A
possible explanation might be that the regulation of some
biomarker serum levels does not primarily occur at the gene
expression levels but at one of several post-transcriptional stages.
Alternatively, it needs to be considered that placenta is a relatively
heterogeneous tissue, consisting of various cell types from the
embryo as well as the mother. Therefore, only a small percentage
of placental cells might produce the specific serum biomarkers, so
that gene expression measurement in placenta as a whole will give
attenuated responses that are statistically more difficult to detect.
A comparison between placenta and fetal liver showed there
were two genes (Ifi27l1 and Sp4) regulated in a similar manner in
both tissues, but not located on the trisomic locus or sex
chromosomes. Concerning the latter, it must be noted that
Laffaire et al. recently described high resolution comparative
genomic hybridization data that show how the translocation of the
distal part of Mmu16 to the telomeric part of Mmu12 in Ts1Cje
mice results in a deletion of a 2 Mb part containing 5 genes
(Dnahc11, Sp4, Sp8, Abcb5 and Itgb8) [43]. Because Ts1Cje mice are
monosomic for this fragment, the lower Sp4 expression found in
both fetal liver and placenta of Ts1Cje mice can therefore
probably be also attributed to a gene dosage effect. When gene
expression data for the other genes in this monosomic locus were
compared, we found that they are not expressed at detectable
levels in either fetal liver or placenta, which explains why there is
no differential expression found for these genes. Ifi27l1 is also
located on chromosome 12, but in an unaffected region, and
therefore its differential expression is presumably independent
from gene dosage effects. However, because Ifi27l1 codes for a
protein that is not located extracellularly, it is not likely to be useful
as a serum biomarker.
An overall comparison between the data obtained for fetal liver
and placenta found that more differentially expressed genes were
found in fetal liver than in placenta, and that the findings in fetal
liver can also be better matched to the pathological features
observed in mice and humans. Although current searches for new
serum biomarkers that can improve the DS screening accuracy are
very much focused on the role of the placenta [50], this study
suggests that fetal liver might nevertheless still be of sufficient value
in this respect to warrant further studies. Indeed, of the fetal liver
hematopoiesis-associated genes, 4 have been suggested as potential
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[10]. Two of these (Pf4, Ppbp) were decreased, whereas both
S100a8 and S100a9 were increased in Ts1Cje mice. We are aware
that any maternal serum level changes in one of these individual
markers might originate in changes in the maternal immune or
hematopoietic system. Therefore, we put forward that follow-up
studies should first determine background levels and variation in
maternal blood, and additionally should not focus on single
proteins, but rather on concurrent changes in these four markers
[38].
In addition to these affected genes shared between both tissues,
we also found 7 trisomic genes that are significantly regulated in
both mouse tissues and potentially detectable in human serum.
These include Sod1 and Dyrk1a, which have been described to be
associated with DS pathogenesis in the literature [17,18,51,52].
The corresponding proteins for these genes might therefore also
provide potential targets for further study in human maternal
serum. Measurement of biomarkers originating in the DS trisomic
genotype can have an extra benefit compared to other potential
markers. DS screening biomarkers that are currently used, or
considered as candidates, are not located on human chromosome
21 and are also predictive for other aneuploidies such as Edwards
syndrome (trisomy 18) and Patau syndrome (trisomy 13). It can be
expected that markers located on the DS region are not only
informative to distinguish DS from normal pregnancies, but also to
differentiate between DS from other kinds of fetal chromosomal
aberrations. This added information might be an additional reason
to include such markers in as screening test.
In DS screening research, the use of omics methods has in
recent years contributed to the identification of several markers
that have the potential to improve DS screening accuracy [7–12].
However, human cohort serum studies are restricted by limited
sample availability, large clinical variations, and additionally
substantial costs in terms of laboratory equipment and reagents.
In several other research fields, animal models are used to partially
overcome such limitations. In this study, we report on the first use
of a mouse model to identify a set of potential targets aimed at
supporting human biomarker studies by providing a more focused
starting position. Altogether, based on our gene expression analysis
we describe 25 targets for DS screening studies (Table 1), 6 of
which (Pf4, Ppbp, S100a8, S100a9, Sod1, Dyrk1a) have been
described earlier to be associated with DS [10,17,18,51,52]. For
these latter 6 targets, we confirmed their differential expression by
quantitative RT-PCR (Supporting Dataset S2). Evidently, since we
identified these new targets in a gene expression study, it still needs
to be determined if the changes in RNA levels result in changes at
the serum protein level that exceed maternal background levels at
a time point suitable for screening. To this end, identification and
validation of these targets at the protein level in human serum
from pregnant women carrying normal and DS fetuses still has to
be performed. As there is ongoing interest [53–55] in how
determining fetal RNA and/or (methylated) DNA in maternal
plasma can detect DS or other aneuploidies, in such further
human studies it might be worth while to find out if such
methodology is applicable to these 25 or even other regulated
genes (Supporting Dataset S3). However, this study, to our
opinion, narrows down the list of potential serum targets to be
studied in subsequent case-control biomarker discovery experi-
ments, which is extremely important given the enormous labor
and financial efforts associated with the identification and
validation of potential biomarkers. In this light, it can also be
noted that in order to efficiently perform further human case-
control experiments on identified targets, the serum measurements
should preferentially be performed by means of a multiplexed
assay to keep the workflow and the amount of required serum
within reasonable limits. In further, more focused studies, assessing
the feasibility of determining serum levels of these 6 targets
combined with the currently used markers in a multiplexed assay
format will therefore have high priority.
Supporting Information
Dataset S1 Primers used for sex and genotype deter-
mination (Microsoft Word document).
(DOC)
Dataset S2 QPCR validation (Microsoft Excel docu-
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Dataset S3 Regulated genes for fetal liver and placenta
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